Showing 3521-3530 of 5773 results for "".
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- Aflibercept 8 mg BLA for Treatment of Wet AMD and DME Accepted for FDA Priority Reviewhttps://modernod.com/news/aflibercept-8-mg-bla-for-treatment-of-wet-amd-and-dme-accepted-for-fda-priority-review/2481433/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review the Biologics License Application (BLA) for aflibercept 8 mg for treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy. The FDA t
- Belkin Vision’s New Glaucoma Laser Technology Now Available in Germanyhttps://modernod.com/news/belkin-visions-new-glaucoma-laser-technology-now-available-in-germany/2481425/Belkin Vision announced that its Direct SLT Eagle device, an automated, non-contact glaucoma laser treatment, is being used to treat glaucoma patients at The University Eye Clinic in Bochum, Germany. “The Eagle by Belkin Vision will be transformative for many of the esti
- FDA Accepts Orasis Pharmaceuticals' NDA for CSF-1 for the Treatment of Presbyopiahttps://modernod.com/news/fda-accepts-orasis-pharmaceuticals-nda-for-csf-1-for-the-treatment-of-presbyopia/2481424/Orasis Pharmaceuticals announced that the FDA has accepted for review its new drug application (NDA) for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 22, 2023. "We
- Alcon Launches "Alcon Experience Academy" App, Expanding On-Demand Learninghttps://modernod.com/news/alcon-launches-experience-academy-app-expanding-remote-on-demand-learning/2481422/Alcon announced the launch of the Alcon Experience Academy (AEA) app, which aims to help optimize eye care professionals’ (ECPs) digital learning experiences. The launch of the app brings AEA’s education and training resources to customers’ fingertips. The customizable
- FDA Accepts Iveric Bio's NDA and Grants Priority Review for Geographic Atrophy Drug Candidatehttps://modernod.com/news/fda-accepts-iveric-bios-nda-and-grants-priority-review-for-geographic-atrophy-drug-candidate/2481418/Iveric bio announced that the FDA has completed its filing review and accepted the company’s new drug application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosahttps://modernod.com/news/frontera-therapeutics-doses-first-patient-in-a-trial-of-ft-002-gene-therapy-for-the-treatment-of-x-linked-retinitis-pigmentosa/2481415/Frontera Therapeutics announced that it has dosed the first patient in a clinical trial of its gene therapy product, FT-002, which is being studied for the treatment of X-linked retinitis pigmentosa (XLRP) and is Frontera’s third gene therapy product candidate to enter the clinic.
- Harrow Launches Next-Generation Compounded Atropine Formulationshttps://modernod.com/news/harrow-launches-next-generation-compounded-atropine-formulations/2481410/Harrow announced the launch of its patent-pending, next-generation compounded atropine formulations. The formulations are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. According to Harrow, the ImprimisRx
- Bruder Healthcare Now Exclusive Licensor of "The Dry Eye Drink"https://modernod.com/news/bruder-healthcare-now-exclusive-licensor-of-the-dry-eye-drink/2481407/Bruder Healthcare, which is part of Hilco Vision, announced an exclusive licensing agreement with Dry Eye Drink LLC, the manufacturer of a portfolio of dry eye products and drink mixes formulated to provide relief for US adults suffering from symptoms of dry eye disease.
- Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis for Wet AMD Meets Primary Endpointhttps://modernod.com/news/opthea-phase-2b-trial-results-of-opt-302-in-combination-with-lucentis-for-wet-amd-meets-primary-endpoint/2481405/Opthea announced that the phase 2b study results of OPT-302, the company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), met the prespecified primary efficacy endpoint.